A Phase 4 interventional study of Anti-Platelet Drugs and Lipid Regulating Drugs in Unstable Angina, sponsored by Jun Li. Status unknown. Open to participants aged 35 Years to 70 Years. Per ClinicalTrials.gov, last updated 2017-06-07.
Sponsored by Jun Li · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study evaluates the clinical efficacy of Gualou Xiebai Banxia Decoction compounded with Danshen Decoction in the treatment of unstable angina pectoris. All of the patients will be divided into 2 arms randomly. One of the arms will be treated by conventional western medicine, the other one will be treated by Gualou Xiebai Banxia Decoction compounded with Danshen Decoction at the base of conventional western medicine.
Gualou Xiebai Banxia Decoction compounded with Danshen Decoction has the effect of promoting blood circulation and resolving phlegm, so it will be used for patients taht belong to phlegm and blood stasis type.
331 studies on the registry are indexed under Angina, Unstable; 45 are open to participants now.
This study's planned enrollment of 120 is below the median of 212 across 201 interventional studies indexed under Angina, Unstable.
Browse Angina, Unstable studies →Jun Li is the lead sponsor of 10 studies on the registry; 1 is open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Patients have at least one of these symptoms:
Exclusion Criteria:
Patients in this group will be treated by Gualou Xiebai Banxia Decoction \& Danshen Decoction at the base of conventional western medicine.
Drug: Anti-Platelet Drugs · Drug: Lipid Regulating Drugs · Drug: Coronary Vasodilator · Drug: Gualou Xiebai Banxia Decoction & Danshen Decoction
Patients in this group will be treated by conventional western medicine, including anti-platelet drugss,lipid regulating drugs, coronary vasodilator, etc.
Drug: Anti-Platelet Drugs · Drug: Lipid Regulating Drugs · Drug: Coronary Vasodilator
Including aspirin and clopidogrel, etc.
Mainly including statins
Mainly including nitrates
Mainly including Fructus Trichosanthis, Rhizoma Pinelliae, Allium, Salvia Miltiorrhiza etc.
Mortality
Death caused by cardiovascular disease
Time frame: Six months after drug intervention
Myocardial enzymes
The unit is mmol/L
Time frame: At baseline and 4 weeks after drug intervention
lood lipid The unit is mmol/L. Blood lipid
The unit is mmol/L.
Time frame: At baseline and 4 weeks after drug intervention
Treadmill exercise test
The result will be positive or negative.
Time frame: At baseline and 4 weeks after drug intervention
The incidence of myocardial infarction or heart failure
Time frame: Six months after drug intervention] Inclusion Criteria:
No study locations are listed for this record.
Plan to share: Undecided
Start is estimated for Jul 2017; primary completion for Oct 2019, 27 months later.
Of 17 phase 4 interventional studies under Angina, Unstable, half reached primary completion within 44 months of starting (the median), counting those still running; a quarter within 26 and three quarters within 51. This study's planned 27 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is status unknown, as verified in Jun 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Jun Li